156 related articles for article (PubMed ID: 30942916)
21. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
Yan M; Roehrl MH; Basar E; Wang JY
Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
[TBL] [Abstract][Full Text] [Related]
22. Anthrax toxin.
Bhatnagar R; Batra S
Crit Rev Microbiol; 2001; 27(3):167-200. PubMed ID: 11596878
[TBL] [Abstract][Full Text] [Related]
23. Antitumor efficacy of a urokinase activation-dependent anthrax toxin.
Rønø B; Rømer J; Liu S; Bugge TH; Leppla SH; Kristjansen PE
Mol Cancer Ther; 2006 Jan; 5(1):89-96. PubMed ID: 16432166
[TBL] [Abstract][Full Text] [Related]
24. Anthrax lethal toxin (LeTx) neutralization by PA domain specific antisera.
Verma M; Suryanarayana N; Tuteja U; Thavachelvam K; Rao MK; Bhargava R; Shukla S
Toxicon; 2017 Dec; 139():58-65. PubMed ID: 28919458
[TBL] [Abstract][Full Text] [Related]
25. Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice.
Moayeri M; Tremblay JM; Debatis M; Dmitriev IP; Kashentseva EA; Yeh AJ; Cheung GY; Curiel DT; Leppla S; Shoemaker CB
Clin Vaccine Immunol; 2016 Jan; 23(3):213-8. PubMed ID: 26740390
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin inhibition of anthrax lethal toxin.
Moayeri M; Wiggins JF; Lindeman RE; Leppla SH
Antimicrob Agents Chemother; 2006 Aug; 50(8):2658-65. PubMed ID: 16870755
[TBL] [Abstract][Full Text] [Related]
27. Development of a novel multiepitope chimeric vaccine against anthrax.
Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
[TBL] [Abstract][Full Text] [Related]
28. Anthrax toxin: structures, functions and tumour targeting.
Liu S; Schubert RL; Bugge TH; Leppla SH
Expert Opin Biol Ther; 2003 Aug; 3(5):843-53. PubMed ID: 12880383
[TBL] [Abstract][Full Text] [Related]
29. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
[No Abstract] [Full Text] [Related]
30. Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.
Wein AN; Liu S; Zhang Y; McKenzie AT; Leppla SH
Invest New Drugs; 2013 Feb; 31(1):206-12. PubMed ID: 22843210
[TBL] [Abstract][Full Text] [Related]
31. Identification of new dominant-negative mutants of anthrax protective antigen using directed evolution.
Wu G; Feng C; Cao S; Guo A; Liu Z
Appl Biochem Biotechnol; 2012 Nov; 168(5):1302-10. PubMed ID: 22948605
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.
Liu S; Ma Q; Fattah R; Bugge TH; Leppla SH
Oncotarget; 2017 Sep; 8(39):65123-65131. PubMed ID: 29029417
[TBL] [Abstract][Full Text] [Related]
33. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
[TBL] [Abstract][Full Text] [Related]
34. Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen.
McCluskey AJ; Olive AJ; Starnbach MN; Collier RJ
Mol Oncol; 2013 Jun; 7(3):440-51. PubMed ID: 23290417
[TBL] [Abstract][Full Text] [Related]
35. Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C.
Wu G; Feng C; Hong Y; Guo A; Cao S; Dong J; Lin L; Liu Z
Appl Microbiol Biotechnol; 2010 Jun; 87(2):609-16. PubMed ID: 20213183
[TBL] [Abstract][Full Text] [Related]
36. Anthrax protective antigen cleavage and clearance from the blood of mice and rats.
Moayeri M; Wiggins JF; Leppla SH
Infect Immun; 2007 Nov; 75(11):5175-84. PubMed ID: 17724066
[TBL] [Abstract][Full Text] [Related]
37. Domain flexibility modulates the heterogeneous assembly mechanism of anthrax toxin protective antigen.
Feld GK; Kintzer AF; Tang II; Thoren KL; Krantz BA
J Mol Biol; 2012 Jan; 415(1):159-74. PubMed ID: 22063095
[TBL] [Abstract][Full Text] [Related]
38. [Toxin-neutralizing monoclonal antibodies to the different domains of anthrax protective antigen].
Xu JJ; Zhang J; Liu SL; Lv TJ; Chen W; Li GL; Ge M; Guo Q
Wei Sheng Wu Xue Bao; 2005 Dec; 45(6):947-51. PubMed ID: 16496709
[TBL] [Abstract][Full Text] [Related]
39. Effects by anthrax toxins on hematopoiesis: a key role for cytokines as mediators.
Rameshwar P; Wong EW; Connell ND
Cytokine; 2012 Jan; 57(1):143-9. PubMed ID: 22082805
[TBL] [Abstract][Full Text] [Related]
40. The CMG2 ELISA for evaluating inhibitors of the binding of anthrax toxin protective antigen to its receptor.
Dawson RM
J Pharmacol Toxicol Methods; 2009; 59(1):50-5. PubMed ID: 19049885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
